Living Document — v4.1 (March 2026)
This protocol evolves as new research emerges. Check DocSandford.com for the latest version.

Therapeutic Yogurt Protocol

A Strain-Specific Fermentation Guide for GI and Metabolic Health

Dr. Adam Sandford, NMD • DocSandford.com

A golden retriever is not a border collie. They're both dogs, but they have completely different skills, temperaments, and jobs. The same is true for probiotic strains. "L. reuteri" is the species — but like dog breeds, the strain determines what it actually does. One strain colonizes your gut and triggers oxytocin. Another produces a potent antimicrobial chemical. A third disrupts the biofilms that pathogenic bacteria hide behind. Using a generic "L. reuteri" product of unknown strain is like hiring a random dog and hoping it herds sheep.

What Is This & Why Make It?

This protocol builds on the pioneering work of Dr. William Davis (Super Gut, Wheat Belly), who popularized extended-fermentation probiotic yogurt. We've refined his approach using the published research on individual strains to create a more targeted, evidence-based protocol — because in personalized probiotic medicine, strain matters.

By fermenting specific bacterial strains in dairy for 36 hours at low temperature, you achieve colony counts in the hundreds of billions per serving — far beyond any capsule. Unlike commercial yogurt (fermented 4–6 hours with generic cultures), this is a targeted biological tool.

What patients typically report: Improved mood and mental clarity. Better sleep. Skin that looks healthier. Reduced bloating and more regular digestion. Less appetite and gradual waist reduction. These aren't guaranteed outcomes — they're commonly reported observations consistent with the published research on these specific strains.

This guide gives you two tracks. Pick your track below, then follow the recipe. Each strain has a brief summary here; the full science is in the Strain Deep-Dive — we recommend reading it to understand why these specific products matter and what differentiates them.

Choose Your Track

If your provider hasn't specified a track, Track A (Metabolic) is the recommended starting point — it has a lower side-effect profile, more immediately noticeable subjective benefits (mood, energy, skin), and doesn't carry the bacteriocin load that Track B does (which can cause die-off symptoms in a healthy gut). Track B is specifically for patients with active GI issues.

Why separate jars for HU58? HU58 doubles every ~2 hours vs. ~3 for the Lactobacillus strains. In a shared jar it would massively outnumber everything else. Ferment separately, then combine at serving or mix into one container for fridge storage — at refrigerator temp, growth stops.

Track B₂ note: Immune Active has only 100M CFU/capsule. Your first 2–3 batches will be thinner. Use each as starter for the next — they'll strengthen progressively.

After GI treatment: For patients on active GI treatment (Track B), this yogurt is one component within your broader personalized treatment plan. When GI symptoms are resolving, Dr. Sandford typically transitions patients to the Metabolic track for ongoing maintenance.

Quick Strain Summaries (full detail in Appendix)

Sourcing Your Ingredients

Dairy: 1 quart of half-and-half per batch (preferred for thickness). Most US half-and-half is ultra-pasteurized (UHT) — see Step 1.

Equipment: Glass jars with lids — Lyellfe 16 oz Short Glass Canning Jars (search Amazon; 3 fit inside a standard Instant Pot). Small whisk. Yogurt maker, sous vide, or Instant Pot with adjustable temp. Kitchen thermometer if heating milk.

You can use a cheaper generic inulin powder instead of Prebio Plus — it'll likely work fine, but it adds a variable when you're already balancing multiple bacterial strains. Prebio Plus controls for that.

The Recipe

What Success Looks Like

After 36 hours, pour off the liquid whey (don't stir it back in — it's stinky). Refrigerate for 2+ hours. A good batch is thick and set — between sour cream and Greek yogurt — with a tangy, pleasantly sour smell. Keeps 7–10 days.

The 36-hour ferment substantially reduces lactose. Most mild-to-moderate lactose intolerance patients tolerate this well at starting doses.

Next Batch Protocol

L. Reuteri jars (Gastrus, Immune Active, or Osfortis) and Biothin: Save 2 tablespoons as starter, or freeze extras as ice cubes for a starter bank. One cube replaces capsules in future batches.

HU58 jar: Fresh capsule every time. Saved HU58 starter is unreliable for spore-formers.

Refresh all strains from new capsules every 8–10 batches to prevent strain drift.

Consumption & What to Expect

Start slow. 1–2 tablespoons/day for the first week → ramp to ½ cup/day over 2–3 weeks. If using two jars, combine in the bowl at serving.

Die-off: Some patients experience temporary worsening in weeks 1–2 (bloating, gas, loose stools, mild headache, fatigue). Hold your dose and let it settle. If significant or not resolving within a week: stop the yogurt and contact our office.

On antimicrobials? If on active SIBO treatment (e.g., Rifaximin), take yogurt at night, separated from medication doses.

Safety Notes

Appendix: Strain Deep-Dive

L. reuteri ATCC PTA 6475 (BioGaia Osfortis)

The colonizer, biofilm-builder, and oxytocin driver.

Oxytocin — far beyond mood. 2023 research shows 6475 stimulates oxytocin production directly from intestinal cells via secretin (Cheng et al., DOI: 10.1038/s41385-023-00496-4). This locally-produced oxytocin regulates gut motility, maintains intestinal barrier integrity, reduces gut inflammation, and modulates visceral pain — all at the mucosal surface, independent of the brain. The systemic effects (wound healing in half the time, bone density, skin/hair, social behavior) require vagus nerve signaling to the hypothalamus (Poutahidis et al., PMID: 24205100). Even dead 6475 cells ("postbiotics") upregulate oxytocin and wound healing in mouse models.

Protective biofilm formation. Forms the densest probiotic biofilms of all L. reuteri strains — ~10x greater density than 17938's parent strain (Jones et al., PMC: PMC2653509). Better colonization, longer persistence, physical exclusion of pathogens.

Reuterin. Produces reuterin but ~8x less per cell than 17938 in biofilm state. Natural trade-off: best colonizers produce less reuterin. 6475 moves in and holds; 17938 clears the field.

Human trials: Bone loss reduction in older women (Nilsson et al. 2018 RCT, PMID: 29926979). IBS improvement combined with 17938 (Cruchet et al. 2024 RCT, DOI: 10.3389/fgstr.2023.1296048). Testosterone: positive in mice, failed in 2024 human RCT.

Vagal tone (extrapolation): 6475's systemic effects require an intact vagus nerve. Plausible that chronic vagal stimulation could improve vagal tone, but not directly measured (e.g., via HRV). Area to watch.

L. reuteri DSM 17938 (BioGaia Immune Active / Protectis)

The reuterin factory and methane-killer.

Reuterin production. ~8x more reuterin per cell than 6475. Broad-spectrum antimicrobial against gram-pos, gram-neg, yeasts, fungi, protozoa.

Methane / IMO. 17938 at 100M CFU twice daily × 4 weeks: methane dropped from 20.8→8.9 ppm (p<0.0001), complete elimination in 11/20 patients (Ojetti et al. 2017, PMID: 28429333). Mechanism: reuterin suppresses hydrogen-producers → starves methane-producing archaea.

Visceral hypersensitivity. Animal data: attenuates dorsal root ganglia hyperexcitability → reduces visceral pain via opioid receptor modulation.

Motility. Improves gastric emptying and colonic transit. 200+ published studies, mostly pediatric. Adult evidence growing.

Does NOT produce histamine. Lacks the hdc gene cluster. Safe for histamine-sensitive patients.

BioGaia Gastrus (17938 + 6475)

The original MIT research product (Poutahidis & Erdman). Both strains at 1:1 ratio, 200M total/capsule. Used in the Cruchet 2024 IBS RCT. Colonizer + killer in matched ratios. Five capsules = 1B total CFU — first batch will be thinner. Freeze some as ice cubes for future starter.

L. gasseri BNR-17 (Dr. Mercola Biothin)

The metabolic strain.

Human RCTs showing reductions in waist circumference, body weight, and visceral fat. Mechanism: converts dietary carbohydrates to indigestible exopolysaccharides (EPS) in the gut, effectively removing calories from absorption. Supports glucose sensitivity and insulin balance. Some IBS-D data (slows rapid transit, reduces diarrhea). Species-level evidence for vaginal health. Originally isolated from human breast milk. Patented strain (AceBiome/Chr. Hansen). Minimal direct SIBO evidence — hence Track A (Metabolic) only.

B. subtilis HU58 (Microbiome Labs)

The biofilm disruptor and bacteriocin powerhouse.

Seven bacteriocins — gram-pos + gram-neg coverage regardless of which bacteria dominate your SIBO.

Pathogen biofilm disruption. Produces surfactin, which physically disrupts pathogen biofilm matrix. In vitro: inhibits Salmonella, E. faecalis, Listeria biofilms. Complementary to 6475 — HU58 tears down enemy biofilms while 6475 builds protective probiotic biofilms. One breaks down pathogen defenses, the other builds your own.

Reduces antibiotic-induced dysbiosis, increases short-chain fatty acids, activates intestinal alkaline phosphatase (reduces endotoxemia). Replaced B. coagulans in the Davis protocol because coagulans fermented unreliably at 100°F.

Davis' MyReuteri / LRDR (Oxiceutics)

Dr. Davis now recommends his proprietary strain "LRDR" sold through Oxiceutics, where he is a paid scientific advisor. The strain identity has not been publicly disclosed, and there are no published studies or genomic data. Many in the Davis community report positive results, and it may be a good strain — we encourage you to try it if you're curious. For this protocol, we've selected strains with published, identified research so we can be specific about what to expect and why. If you've used MyReuteri and have direct experiences to share, we'd genuinely like to hear them — that community-level data helps all of us understand what LRDR may offer.

This guide is for patients of Dr. Adam Sandford, NMD. It is not a substitute for individualized medical advice. Strain-specific effects reflect published research as of early 2026. Contact our office: DocSandford.com